WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶:

C23C 14/34

(11) International Publication Number: WO 98/27246

(43) International Publication Date: 25 June 1998 (25.06.98)

(21) International Application Number: PCT/US97/23377

(22) International Filing Date: 15 December 1997 (15.12.97)

(30) Priority Data:

08/769,240 18 December 1996 (18.12.96) US 08/867,888 3 June 1997 (03.06.97) US

(71) Applicant: IMPLANT SCIENCES CORP. [US/US]; 107
Audubon Road #5, Wakefield, MA 01880-1246 (US).

(72) Inventors: ARMINI, Anthony, J.; 5 Skytop Drive, Manchester, MA 01944 (US). BUNKER, Stephen, N.; 95 Audubon Road #1114, Wakefield, MA 01880 (US).


(74) Agents: BLODGETT-FORD, Sayoko, J. et al.; Foley, Hoag & Eliot LLP, One Post Office Square, Boston, MA 02109 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: SPUTTER CATHODE FOR APPLICATION OF RADIOACTIVE MATERIAL



(57) Abstract

Making a sputter cathode for applying a radioactive material includes obtaining a wafer composed of a base material and a stable precursor. The base material is transmutable into a material having a relatively short atomic half-life. The wafer is atomically activated to transmute a portion of the stable precursor into a radioactive material. Atomically activating the wafer may include exposing the wafer to a source of thermal neutrons by, for example, placing the wafer in a high-flux nuclear reactor for approximately four weeks.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

Albania	ES	Spain	LS	Lesotho	SI	Slovenia
Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
Austria	FR	France	LU	Luxembourg	SN	Senegal
Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
Brazil	IL	Israel	MR	Mauritania	UG	Uganda
Belarus	IS	Iceland	MW	Malawi	US	United States of America
Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
Congo	KE	Кепуа	NL	Netherlands	YU	Yugoslavia
Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
Cameroon		Republic of Korea	PL	Poland		
China	KR	Republic of Korea	PT	Portugal		
Cuba	KZ	Kazakstan	RO	Romania		
Czech Republic	LC	Saint Lucia	RU	Russian Federation		
Germany	LI	Liechtenstein	SD	Sudan		
Denmark	LK	Sri Lanka	SE	Sweden		
Estonia	LR	Liberia	SG	Singapore		
	Armenia Austraia Austraia Australia Azerbaijan Bosnia and Herzegovina Barbados Belgium Burkina Faso Bulgaria Benin Brazil Belarus Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon China Cuba Czech Republic Germany Denmark	Armenia FI Austria FR Australia GA Azerbaijan GB Bosnia and Herzegovina GE Barbados GH Belgium GN Burkina Faso GR Bulgaria HU Benin IE Brazil IIL Belarus IS Canada IT Central African Republic JP Congo KE Switzerland KG Côte d'Ivoire KP Cameroon China KR Cuba KZ Czech Republic LC Germany LI Denmark LK	Armenia FI Finland Austria FR France Australia GA Gabon Azerbaijan GB United Kingdom Bosnia and Herzegovina GE Georgia Barbados GH Ghana Belgium GN Guinea Burkina Faso GR Greece Bulgaria HU Hungary Benin IE Ireland Brazil IL Israel Belarus IS Iceland Canada IT Italy Central African Republic JP Japan Congo KE Kenya Switzerland KG Kyrgyzstan Côte d'Ivoire KP Democratic People's Cameroon China KR Republic of Korea Cuba KZ Kazakstan Czech Republic LC Saint Lucia Germany LI Liechtenstein Denmark LK Sri Lanka	Armenia FI Finland LT Austria FR France LU Australia GA Gabon LV Azerbaijan GB United Kingdom MC Bosnia and Herzegovina GE Georgia MD Barbados GH Ghana MG Belgium GN Guinea MK Burkina Faso GR Greece Bulgaria HU Hungary ML Benin IE Ireland MN Brazil IIL Israel MR Belarus IS Iceland MW Canada IT Italy MX Central African Republic JP Japan NE Congo KE Kenya NL Switzerland KG Kyrgyzstan NO Côte d'Ivoire KP Democratic People's NZ Cameroon RR China KR Republic of Korea PL China KR Republic G KOREA Czech Republic LC Saint Lucia RU Germany LI Liechtenstein SD Denmark LK Sri Lanka SE	Armenia FI Finland LT Lithuania Austria FR France LU Luxembourg Australia GA Gabon LV Latvia Azerbaijan GB United Kingdom MC Monaco Bosnia and Herzegovina GE Georgia MD Republic of Moldova Barbados GH Ghana MG Madagascar Belgium GN Guinea MK The former Yugoslav Burkina Faso GR Greece Republic of Macedonia Bulgaria HU Hungary ML Mali Benin IE Ireland MN Mongolia Brazil II Israel MR Mauritania Belarus IS Iceland MW Malawi Canada IT Italy MX Mexico Central African Republic JP Japan NE Niger Congo KE Kenya NL Netherlands Switzerland KG Kyrgyzstan NO Norway Côte d'Ivoire KP Democratic People's NZ New Zealand Cameroon Republic of Korea PL Poland China KR Republic of Korea PT Portugal Cuba KZ Kazakstan RO RO Romania Czech Republic LC Saint Lucia RU Russian Federation Germany LI Liechenstein SD Sudan Denmark LK Sri Lanka SE Sweden	Armenia FI Finland LT Lithuania SK Austria FR France LU Luxembourg SN Australia GA Gabon LV Latvia SZ Azerbaijan GB United Kingdom MC Monaco TD Bosnia and Herzegovina GE Georgia MD Republic of Moldova TG Barbados GH Ghana MG Madagascar TJ Belgium GN Guinea MK The former Yugoslav TM Burkina Faso GR Greece Republic of Macedonia TR Bulgaria HU Hungary ML Mali TT Benin IE Ireland MN Mongolia UA Brazil IIL Israel MR Mauritania UG Belarus IS Iceland MW Malawi US Canada IT Italy MX Mexico UZ Central African Republic JP Japan NE Niger VN Congo KE Kenya NL Netherlands YU Switzerland KG Kyrgyzstan NO Norway ZW Côte d'Ivoire KP Democratic People's NZ New Zealand Cameroon Republic IC Saint Lucia RU Russian Federation Germany LI Liechtenstein SD Sudan Denmark LK Sri Lanka SE Sweden

SPUTTER CATHODE FOR APPLICATION OF RADIOACTIVE MATERIAL

This application is a continuation-in-part of U.S. patent application No. 08/769,240 filed on December 18, 1996, and U.S. patent application no. 08/867,888, filed on June 3, 1997, both of which are pending.

Technical Field

5

15

20

This application relates to the field of manufacturing radioactive objects and more particularly to the field of manufacturing radioactive objects that are surgically implanted.

10 Background of The Invention

In many instances, it is desirable to cause a normally non-radioactive object to become radioactive by imbedding or applying radioactive material to the normally non-radioactive object. For instance, in the case of intra-arterial stents used to prevent restenosis or reclosure of the artery subsequent to balloon angioplasty or atherectomy, it has been found that causing the stent to be radioactive irradiates the tissue in close proximity to the implantation site of the stent, thus reducing rapid tissue growth around the stent. Reducing the rapid tissue growth decreases the likelihood of restenosis.

A radioactive stent described in U.S. Patent No. 5,059,166 to Fischell et al. (the '166 patent) shows a helical spring stent that is caused to be radioactive prior to insertion into the artery. The '166 patent discusses various techniques for causing the stent to be radioactive, including using radioisotopes in the manufacture of the stent

2

and/or plating the stent with a radioisotope coating. Although the '166 patent generally describes a process for making the stent radioactive, it may be assumed that using radioisotopes and/or applying a radioactive coating would require handling of radioactive material in a manner which may be unacceptable for mass production purposes.

5

10

15

20

An alternative approach for creating a radioactive stent involves using a cyclotron to bombard stainless steel stents with a proton beam to produce radioactive isotopes within the stent. However, these isotopes have high-energy gamma emissions and long half-lives that make this technique impractical for humans. Gamma emissions increase the whole-body dose of radiation while having relatively little therapeutic effect on local tissue compared to the effect of beta emissions. In addition, it has been found that long half-life materials are less appropriate since optimum radioactivity-mediated inhibition is more likely to be achieved by a continuous exposure for the first few weeks following the insertion of the stent. Accordingly, a half-life of a few weeks (i.e., one to seven weeks) is deemed ideal for this purpose.

Another technique for manufacturing radioactive stents involves first implanting massive doses of ³¹P in titanium stents. The ³¹P is subsequently activated by a nuclear reactor to produce ³²P. However, this technique requires up to thirty atomic percent ³¹P under the surface of the titanium stent, which alters the chemical composition of the alloy with unpredictable effects on the mechanical and biocompatibility properties of the stent. In addition, the titanium metal stent may have impurities which, when bombarded in a nuclear reactor, create isotopes that emit

3

substantial gamma rays and have long half-lives similar to the isotopes in the stainlesssteel stents that are bombarded in a nuclear reactor.

An article titled, "Production and Quality Assessment of Beta Emitting P-32

Stents for Applications in Coronary Angioplasty", by Janicki et al. discusses using ion beam implantation to implant radioactive ³²P isotopes into a titanium stent. Although the ion beam implantation technique itself appears to result in a radioactive stent having acceptable characteristics, Janicki et al. disclose performing the ion beam implantation using radioactive cathodes that are prepared using radioactive salts which are first dissolved into liquids and then dried onto the cathode. Handling the thusformed radioactive liquids may be unacceptable for mass production. In addition, the resulting radioactive salts that are dried onto the cathode may fall off and contaminate workers in a mass production setting.

Summary Of The Invention

5

10

15

20

According to the present invention, manufacturing a sputter cathode for applying a radioactive material includes obtaining a wafer containing a base material and a stable precursor, the base material being transmutable into a material having a relatively short atomic half-life, and atomically activating the wafer to transmute a portion of the stable precursor into a radioactive material. The term "wafer" as it is used herein will be understood to encompass all solid forms, including but not limited to chunks, pieces, powders and chips. The "stable precursor" may include, for example, any phosphide or any metal phosphide. The wafer material may be selected from the group consisting of: silicon phosphide and gallium phosphide and the

4

radioactive material may be ³²P. The wafer may contain between 0.01 and 50 atomic percent ³¹P. Alternatively, the wafer material may be selected from the group consisting of: magnesium sulphide, aluminum sulphide, and gallium sulphide and the radioactive material may be ³⁵S.

5

10

Atomically activating the wafer may include exposing the wafer to a source of thermal neutrons by placing the wafer in a high-flux nuclear reactor for approximately four weeks. The wafer may be approximately circularly shaped and have a diameter of 4 inches and a thickness of 0.5 mm. Prior to atomically activating the wafer, the wafer may be cut into portions suitable for use as a sputter-type ion source of an ion beam implantation device. The wafer may be configured to operate in connection with a magnetron sputter coating device. Prior to atomically activating the wafer, a coating material that is transmutable into a material having a relatively short atomic half-life may be applied. The coating material may be less than 10 microns thick. The coating material may be the same as the base material.

15

20

According further to the present invention, a solid-state radioactive cathode, includes a wafer having a base material and a stable precursor, wherein the base material is transmutable into a material having a relatively short atomic half-life. The cathode may also include a surface coating material, substantially encapsulating the cathode, that is transmutable into a material having a relatively short atomic half-life. The surface coating material may be less than 10 microns thick and may be the same as the base material. The wafer may have a substantially circular shape, a diameter of approximately four inches, and a thickness of approximately 0.5 mm. The cathode

5

may be configured to be used in a magnetron sputtering device. The wafer may have a substantially square shape, an edge length of approximately 2 cm., and a thickness of approximately 0.5 mm. The cathode may be configured to be used as a sputter-type source of an ion implantation device.

5

10

The cathode may include material selected from the group consisting of: silicon phosphide and gallium phosphide and the radioactive material may be ³²P. The wafer may contain between 0.01 and 50 atomic percent ³¹P. Alternatively, the wafer material may be selected from the group consisting of: magnesium sulphide, aluminum sulphide, and gallium sulphide and the radioactive material may be ³⁵S.

Brief Description Of Drawings

FIG.'s 1A and 1B show a top view and side view, respectively, of a sputter cathode according to the present invention.

FIG. 2 is a schematic diagram illustrating use of the sputter cathode in a magnetron-type sputtering device.

15

FIG. 3 is a schematic diagram showing use of the sputter cathode in an ion beam implantation device.

6

FIG. 4 is a graph indicating a relationship between depth of penetration in a stent and concentration of ³²P atoms.

FIG. 5 is a graph indicating a relationship between depth of penetration in a silicon wafer and concentration of ³¹P atoms.

5 Detailed Description Of The Preferred Embodiments

Referring to FIG.'s 1A and 1B, a radioactive sputter cathode 20 includes a radioactive central portion 22 and a non-radioactive coating 24. In the embodiment illustrated herein, the cathode 20 is an approximately circularly-shaped wafer having a diameter of about four inches and a thickness of about 0.5 mm. However, as will become apparent from the following discussion, the technique disclosed herein may be used to provide sputter cathodes of numerous sizes and shapes depending upon the ultimate end use of the cathode. In the embodiments illustrated herein, the cathode 20 is made sufficiently thin to be used in a magnetron sputtering device and/or as a sputter source in an ion beam implantation device.

15

10

A radioactive central portion 22 includes a silicon base having, for example, radioactive ³²P embedded therein. The non-radioactive coating 24 encapsulates the radioactive central portion 22 and is provided in order to facilitate handling of the cathode 20. The non-radioactive coating 24 may be made of silicon and have a thickness of 10 microns or less.

7

Referring to FIG. 2, the cathode 20 may be used in a chamber 30 of a conventional magnetron sputtering device, such as that manufactured by AJA International, Inc. of Scituate, Massachusetts. The sputtering device includes a conventional driver 32 that drives material from the cathode 20. In the example illustrated in FIG. 2, a helical spring intra-arterial stent 34 is shown being coated by the material driven from the cathode 20. Since the cathode 20 contains radioactive material (e.g., ³²P), then driving material from the cathode 20 in the direction of the stent 34 causes the stent to be coated with the same radioactive material. The thusformed radioactive stent 34 may be used in humans subsequent to balloon angioplasty to prevent restenosis, as described in, for example, U.S. Patent No. 5,059,166 to Fischell et al., which is incorporated herein by reference.

5

10

15

20

Note that ³²P is an especially desirable material for coating the stent 34 since ³²P emits only beta rays (or at least greater than 99.99 % beta rays) as opposed to gamma rays and has a relatively short (14 day) half-life. Note also that in this application, the stent may be made of stainless steel, titanium, nitinol, or any other material suitable for accepting the ³²P coating as applied by the sputtering device and for being used in humans to prevent restenosis.

Referring to FIG. 3, the sputter cathode 20 may be used in connection with a conventional ion beam implantation device 40, such as the Eaton NV-3206 manufactured by Eaton Corporation of Austin, Texas. In this instance, the device 40 uses an approximately square portion of the cathode 20 measuring approximately 2 cm. by 2 cm. Such a portion may be obtained by cutting the approximately four-inch

8

diameter wafer shown in FIG.'s 1A and 1B into squares measuring approximately 2 cm. by 2 cm. The cathode 20 may be cut using conventional means, such as a diamond saw. Cutting the cathode 20 is discussed in more detail hereinafter.

The ion beam implantation device 40 includes an arc chamber 42 containing the cathode 20 and containing a filament 44. During operation, the arc chamber 42 is continuously filled with argon gas via an inlet 46. A negative electrical bias 48 is connected to the cathode 20 and the chamber in order to place a strong negative bias on the cathode 20.

5

10

15

20

The combination of heating the filament 44 and applying the negative voltage bias to the cathode 20 cause ions to exit from the arc chamber 42 through an evacuation slit formed by a pair of electrodes 52a, 52b. The ions that exit from the arc chamber 42 include ions from the cathode 20 along with ions of the argon gas.

The various ions are separated in a conventional manner by a mass analysis magnet 54 which causes an ion beam containing primarily the ³²P ions to pass through a mass analysis slit 56 and strike a helical spring stent 58, which is similar to the stent 34 discussed above in connection with FIG. 2. In a preferred embodiment, the stent 58 is made of stainless steel, although the stent 58 may be made of other material such as titanium, nitinol, or any other suitable material capable of being implanted via the ³²P ion beam and used in humans. Operation of the ion beam implantation device 40 occurs primarily in a vacuum of 10⁻⁶ torr.

Referring to FIG. 4, a graph 60 illustrates concentration of the ³²P at various depths in the stent 58 upon implantation via the device 40. The graph 60 includes a first vertical axis 62 indicating the number of atoms of ³²P per cubic centimeter of material and a horizontal axis 64 indicating depth of penetration (i.e., the distance from the surface of the stent 58). A second vertical axis 66 indicates atomic percent of ³²P atoms. Note that since the atomic percent of ³²P atoms is directly proportional to the number of ³²P atoms per cubic centimeter of material, then the first vertical axis 62 and the second vertical axis 66 represent essentially the same characteristic expressed in a different manner.

10

15

20

5

A plot 68 of the graph 60 indicates the number of ³²P atoms per cubic centimeter (and indicates the atomic percent of ³²P atoms) as a function of the depth of penetration within the stent 58. Note that in this particular example, the plot 68 indicates that the number of ³²P atoms per cubic centimeter peaks at a depth of approximately 1200 angstroms and that the peak value is approximately 2.8 x 10⁻¹⁴ ³²P atoms per cubic centimeter of material. The peak value occurs at 1200 angstroms below the surface because the ion beam implantation device 40 embeds the atoms into the stent 58 using relatively high velocity ions. Of course, the plot 68 shown in FIG. 4 is exemplary only and a variety of other distributions are possible depending upon a number of factors including the nature of the cathode material, the nature of the material used to make the stent 58, the type of ion beam implantation device 40, and other operational factors familiar to one of ordinary skill in the art.

In one embodiment, the cathode 20 is manufactured using established

10

semiconductor technology in which a wafer-shaped base material of hyper-pure single crystal silicon is doped with a stable precursor of ³¹P using a spin-on dopant of phosphorosilica film (such as that made by the Emulsitone Company of Whippany, New Jersey). In this embodiment, the ³¹P is driven into the silicon using an 1170°, seven-day drive-in. However, alternative embodiments may use drive-ins ranging between 10 and 1,000 hours and temperatures ranging between 1000 and 1300°C. Note that instead of using a spin-on a dopant, one could embed the surface with phosphorus by ion implantation followed by a high temperature drive-in. Alternatively still, it may be possible to obtain an Si/³¹P alloy or to obtain silicon (or another suitable base material) that is heavily doped with a stable precursor such as ³¹P. The wafer may have dimensions similar to those discussed above in connection with FIG.'s 1A and 1B.

Referring to FIG. 5, a graph 70 illustrates concentration of ³¹P at various depths in the wafer-shaped base material. The graph 70 includes a first vertical axis 72 indicating the number of atoms of ³¹P per cubic centimeter of material and a horizontal axis 74 indicating depth of penetration. A second vertical axis 76 indicates atomic percent of ³¹P atoms. Just as with FIG. 4, the atomic percent of ³¹P atoms is directly proportional to the number of ³¹P atoms per cubic centimeter so that the first vertical axis 72 and the second vertical axis 76 represent essentially the same characteristic expressed in a different manner.

20

15

5

10

A plot 78 of the graph 70 indicates the number of ³¹P atoms per cubic centimeter as a function of the depth of penetration within the base material. In this embodiment, the plot 78 shows the highest concentration of ³¹P atoms at the surface of

11

the base material with the concentration monotonically decreasing as the depth of penetration increases. Of course, the plot 78 shown in FIG. 5 is exemplary only and a variety of other distributions are possible depending upon a number of factors including the nature of the base material, the nature of the stable precursor, the drive-in time and temperature, and a variety of other operational factors familiar to one of ordinary skill in the art.

Following diffusion of the ³¹P into the silicon, the base material is provided with a sealant coating of silicon using conventional means such as a commercial sputtering device. In the embodiment illustrated herein, the coating is less than 10 microns thick.

10

15

20

5

Following the coating step, the stable precursor, ³¹P, is atomically activated by placing the wafer in a nuclear reactor which transmutes a portion of the ³¹P into ³²P, which is a pure beta emitter suitable for coating or being implanted into intra-arterial stents, as described above. If the dimensions of the wafer are too large for the intended end application, then the wafer may be cut (using, for example, a diamond saw) prior to being placed in the nuclear reactor. For instance, if a wafer having a four-inch diameter such as that discussed above in connection with FIG.'s 1A and 1B is used, then the wafer may be cut into squares measuring 2 cm. x 2 cm. if it is desired that the wafer be used in the Eaton NV-3206 ion implantation device 40, discussed above. In the embodiment illustrated herein, the wafer (or portions of the wafer) are atomically activated by being placed in a high-flux nuclear reactor for approximately four weeks, although it will be appreciated by one of ordinary skill in the art that the wafer may be atomically activated using any source of thermal neutrons.

Note that although the silicon base of the wafer is bombarded in the nuclear reactor, the (substantially pure) silicon is transmuted into ³¹Si, which has a relatively short half-life (2.62 hours) and which, incidentally, decays into ³¹P. The thus-activated silicon will therefore become stable in a relatively short period of time (e.g., one week). Note also that using hyper-pure silicon reduces the likelihood of impurities being activated in the reactor and producing undesirable isotopes.

In an alternate embodiment, the combination of base material and stable precursor may be a chemical compound such as gallium phosphide (GaP). In this case, the base element (gallium) activates in the reactor with a half life significantly shorter than the stable precursor (phosphorus). Note that gallium phosphide in single crystal, ultra-pure form is presently available for use in the manufacture of red light-emitting diodes. For the purposes described herein, having the GaP be relatively pure is useful because unwanted impurities could activate in the nuclear reactor to form very long-lived gamma emitting radioisotopes which would be dangerous to load into an ion source.

As an example, a four week high neutron flux activation of a GaP chip in the University of Missouri research reactor yields the following:

Size of GaP chip:

1 cm x 1 cm x 0.24 mm

GaP weight:

100 mg

Irradiation time:

30 days

Activities at reactor exit:

 $^{32}P (T \frac{1}{2} = 14.3 \text{ days})$:

259 mCi

 72 Ga (T $\frac{1}{2}$ = 14.1 hrs):

18.8 Ci

Activities after cooling 20 days:

 $^{32}p.$

97 mCi

20

5

10

15

25

13

 72 Ga: 0.001 μ Ci

In this example, the gallium base does not have any significant activity after twenty days of decay. It is also possible to use silicon in place of gallium so that the base material/stable precursor combination is silicon phosphide (SiP).

5

In still another alternate embodiment, a chemical compound such as magnesium sulfide may be used to manufacture a sputter cathode for ion implantation of ³⁵S, a radioisotope with a 87.2 day half-life which also emits beta radiation with extremely little, if any, gamma emission. In this case, the magnesium is the base material and the sulfur is the stable precursor.

10

For magnesium sulfide, the magnesium activates to ²⁷Mg which has a half-life of 9.45 minutes. Thus, at the end of a reactor activation of, for example, thirty days, a cool time of only 5 days will reduce the ²⁷Mg activity to essentially zero leaving a substantially pure source of ³⁵S with an 87.2 day half-life. Ion implantation of ³⁵S will be of value in those stents or cancer treatment probes where a much longer irradiation may be indicated. Aluminum or gallium may be used in place of magnesium so that the base material/stable precursor combination is either aluminum sulfide or galium sulfide. For any of the alternative embodiments discussed herein, the wafers may be coated and generally subjected to other follow-on processing as discussed above in connection with any of the embodiments. In all cases, the coating may be the same as, or different from, the base material.

20

15

as a stable precursor, the invention may be practiced using any base material that can accept the stable precursor and that activates to a relatively short half-life radioisotope, such as germanium. Note also that the material used to provide the sealed coating may be different than the base material used to accept the stable precursor, but that it is desirable that the material used for the coating have a relatively short half-life. In addition, although the invention has been illustrated herein using ³¹P as a stable precursor, the invention may be practiced using any material as a stable precursor provided that the material may be activated in a reasonable amount of time within a nuclear reactor (or other atomic activation means). The use of ³¹P is especially advantageous in the present application since the resulting transmuted element, ³²P, emits only beta rays (or at least greater than 99.99 % beta rays) which, as discussed above, is advantageous in use with intra-arterial stents or possibly other human implants. However, for other applications, it may be desirable to use a different atomic precursor having different characteristics when the precursor is atomically activated.

In addition, it will also be appreciated by one of ordinarily skill in the art that the invention includes making wafers of any number of different sizes and shapes depending upon the ultimate end-use of the wafer. The invention may be practiced without including the sealed coating on the wafer, although a wafer not having a sealed coating may be more difficult to handle since such a wafer would have atomically activated material on the outside surface thereof, thus increasing the likelihood that the atomic material could rub off or be brushed off of the final end product. The invention does not depend on how the stable precursor is dissolved into the base material.

15

While the invention has been disclosed in connection with the preferred embodiments shown and described in detail, various modifications and improvements thereon will become readily apparent to those skilled in the art. Accordingly, the spirit and scope of the present invention is to be limited only by the following claims.

16

What is claimed is:

1. A method of manufacturing a sputter cathode for applying a radioactive material, comprising the steps of:

- (a) obtaining a wafer composed of a base material and a stable precursor, wherein the base material is transmutable into a material having a relatively short atomic half-life; and
- (b) atomically activating the wafer to transmute a portion of the stable precursor into a radioactive material.
- 2. A method according to claim 1, wherein the wafer includes material selected from the group consisting of: silicon phosphide and gallium phosphide
- 3. A method according to claim 1, wherein the wafer includes material selected from the group consisting of the metal phosphides plus boron phosphide and silicon phosphide.
- 4. A method according to claim 1, wherein atomically activating the wafer includes exposing the wafer to a source of thermal neutrons.
- 5. A method according to claim 1, wherein the wafer is approximately circularly shaped and has a diameter of 4 inches and a thickness of 0.5 mm.
- 6. A method according to claim 1, further comprising the step of:

17

- (c) prior to atomically activating the wafer, cutting the wafer into portions suitable for use as a sputter-type ion source of an ion beam implantation device.
- 7. A method according to claim 1, wherein the wafer is configured to operate in connection with a magnetron sputter coating device.
- 8. A method according to claim 1, further comprising the step of:
 - (c) prior to atomically activating the wafer, applying a coating material that is transmutable into a material having a relatively short atomic half-life.
- 9. A method according to claim 2, wherein the radioactive material is ³²P.
- 10. A method according to claim 2, wherein the wafer is an alloy or mixture containing between 0.01 and 50 atomic percent ³¹P.
- 11. A method according to claim 3, wherein the radioactive material is 35S.
- 12. A method according to claim 4, wherein exposing the wafer to a source of thermal neutrons includes placing the wafer in a high-flux nuclear reactor for approximately four weeks.
- 13. A method according to claim 8, wherein the coating material is less than 10 microns thick.

18

- 14. A method according to claim 8, wherein the coating material is the same as the base material.
- 15. A solid-state radioactive cathode, comprising:

a wafer that includes a base material and a stable precursor, wherein the base material is transmutable into a material having a relatively short atomic half-life.

- 16. A solid-state radioactive cathode, according to claim 15, further comprising: a surface coating material, substantially encapsulating the cathode, the surface coating material being transmutable into a material having a relatively short atomic half-life.
- 17. A solid-state radioactive cathode, according to claim 15, wherein the wafer has a substantially circular shape, a diameter of approximately four inches, and a thickness of approximately 0.5 mm.
- 18. A solid-state radioactive cathode, according to claim 15, wherein the wafer has a substantially square shape, an edge length of approximately 2 cm., and a thickness of approximately 0.5 mm
- 19. A solid-state radioactive cathode, according to claim 15, wherein the wafer includes a chemical compound selected from the group consisting of the metal phosphides plus boron phosphide and silicon phosphide.


PCT/US97/23377

19

20. A solid-state radioactive cathode, according to claim 15, wherein the wafer contains between 0.01 and 50 atomic percent ³¹P.

WO 98/27246

- 21. A solid-state radioactive cathode, according to claim 15, wherein the wafer includes of a chemical compound selected from the group consisting of: magnesium sulphide, aluminum sulphide, and gallium sulphide
- 22. A solid-state radioactive cathode, according to claim 16, wherein the surface coating material is less than 10 microns thick.
- 23. A solid-state radioactive cathode, according to claim 16, wherein the coating material is the same as the base material.
- 24. A solid-state radioactive cathode, according to claim 17, wherein the cathode is configured to be used in a magnetron sputtering device.
- 25. A solid-state radioactive cathode, according to claim 18, wherein the cathode is configured to be used as a sputter-type source of an ion implantation device.
- 26. A solid-state radioactive cathode, according to claim 19, wherein the radioactive material is ³²P.
- 27. A solid-state radioactive cathode, according to claim 21, wherein the radioactive material is ³⁵S.






Fig. 2

SUBSTITUTE SHEET (RULE 26)






Fig. 3



SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

Int tional Application No PCT/US 97/23377

	FICATION OF SUBJECT MATTER C23C14/34					
-According to	International Patent Classification (IPC) or to both national classificat	ion and IPC				
B. FIELDS	SEARCHED					
Minimum do IPC 6	cumentation searched (classification system followed by classification C23C	symbols)				
Documentati	ion searched other than minimumdocumentation to the extent that sur	ch documents are included in the fields sea	rched			
Electronic da	ata base consulted during the international search (name of data base	e and, where practical, search terms used)				
	ENTS CONSIDERED TO BE RELEVANT					
Category °	Citation of document, with indication, where appropriate, of the relev	vant passages	Relevant to claim No.			
Х	GOLDYS E M ET AL: "Germanium-dop gallium phosphide obtained by neu irradiation"	1-4,15, 19,21				
	JOURNAL OF APPLIED PHYSICS, 15 AUG. 1993, USA, vol. 74, no. 4, ISSN 0021-8979, pages 2287-2293, XP002063299 see paragraph II-III					
Α	US 5 342 283 A (GOOD ROGER R) 30 1994 see column 70, line 52 - line 64	1-27				
	_	/				
		715,00770				
X Further documents are listed in the continuation of box C. X Patent family members are listed in annex.						
* Special categories of cited documents : "T" later document published after the international filing date or priority date and not in conflict with the application but						
"E" earlier document but published on or after the international "It was date." "It was date." "It was document of particular relevance invention "It was date." "It was document of particular relevance; the claimed invention						
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the						
other r	ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filling date but aan the priority date ctalmed	document is combined with one or more other such docu- ments, such combination being obvious to a person skilled in the art. "document member of the same patent family				
Date of the actual completion of theinternational search Date of mailing of the international search report						
2	4 April 1998	08/05/1998				
Name and r	nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk	Authorized officer				
	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Ekhult, H				

1

INTERNATIONAL SEARCH REPORT

Intitional Application No PCT/US 97/23377

1

INTERNATIONAL SEARCH REPORT

information on patent family members

In Itional Application No
PCT/US 97/23377

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US 5342283 A	30-08-94	AU 8920791 A CA 2067804 A EP 0500928 A JP 5503303 T WO 9203179 A	17-03-92 14-02-92 02-09-92 03-06-93 05-03-92	

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

□ OTHER: _____